Dentistry for osteoporosis and cancer patients

摘要

Bisphosphonates (BPs) and similarly acting bone antiresorptive agents such as denosumab are becoming the principal if not sole therapeutic agents for the preventative treatment against fracture occurrence in osteoporosis (OP) patients. BPs are also increasingly used in the treatment of severely painful and potentially life-shortertening bone complications, including fracture occurrence, in cancer patients. rapid expansion of research focused on the prevention and treatment of osteonecrosis of the jaw (ONT) but also the emergence of a new sub-specialty focusing on the diagnosis, prevention and treatment of ONJ?